Potential Role of miRNAs as Theranostic Biomarkers of Epilepsy

Claudia Cava,1,4 Ida Manna,2,4 Antonio Gambardella,3 Gloria Bertoli,1 and Isabella Castiglioni1

Epilepsy includes a group of disorders of the brain characterized by an enduring predisposition to generate epileptic seizures. Although familial epilepsy has a genetic component and heritability, the etiology of the majority of non-familial epilepsies has no known associated genetic mutations. In epilepsy, recent epigenetic profiles have highlighted a possible role of microRNAs in its pathophysiology. In particular, molecular profiling identifies a significant number of microRNAs (miRNAs) altered in epileptic hippocampus of both animal models and human tissues. In this review, analyzing molecular profiles of different animal models of epilepsy, we identified a group of 20 miRNAs commonly altered in different epilepsy-animal models. As emerging evidences highlighted the poor overlap between signatures of animal model tissues and human samples, we focused our analysis on miRNAs, circulating in human biofluids, with a principal role in epilepsy hallmarks, and we identified a group of 8 diagnostic circulating miRNAs. We discussed the functional role of these 8 miRNAs in the epilepsy hallmarks. A few of them have also been proposed as therapeutic molecules for epilepsy treatment, revealing a great potential for miRNAs as theranostic molecules in epilepsy.

Epilepsy is a global health care issue affecting 50–70 million people worldwide with 2.4 million people being diagnosed with epilepsy each year.1 It affects ∼1% of the population worldwide at the age of 20 years and 3% at the age of 75 years;2 ∼80% of epilepsy cases occur in the developing countries, and three-fourths of the affected individuals do not get appropriate treatment.1

Epilepsy is a highly heterogeneous condition that encompasses a spectrum of clinical subtypes sharing the common feature of persistently increased neuronal excitability and spontaneous seizure generation. Although clinical classifications are constantly evolving, in 2017, the International League Against Epilepsy (ILAE) announced new classification schemes for both seizures and epilepsies, and it proposed to classify epilepsies on seizure types, epilepsy types, and epileptic syndromes, dividing seizures into focal onset and generalized onset.3–6

Traditional estimates of heritability for epilepsy varied greatly, and growing evidence has illustrated that genetic factors may play a role in many epilepsy syndromes.5–8 A recent work reported heritability as 32% for all epilepsy classes, 23% for focal epilepsy, and 36% for nonfocal epilepsy.7

Currently available interventions and antiepileptic drugs (AEDs) are not effective in over 30% of the patients.4 Most of these AEDs are primarily targeted against neuronal ion channels or neuronal receptors, such as gamma-aminobutyric acid (GABA) and glutamate receptors.9 Thus, there is a need to better understand the underlying disease mechanisms in order to identify novel drug targets or treatment strategies.10

The pathogenesis of epilepsy is supposed to involve large-scale alterations in the expression of genes controlling neurotransmitter signaling, ion channels, synaptic structure, neuronal death, gliosis, and inflammation.11

Numerous gene defects underlying different forms of epilepsy have been identified, with most of these genes encoding ion channel proteins.12 However, the etiology of the majority of non-familial epilepsies has no known associated genetic mutations, even though genetic linkage analyses have identified several loci that may contain mutation-susceptible sequences in epilepsy.13 Copy number variants associated with epilepsies have been observed through genome-wide analysis, and single-point mutations have been detected through exome sequencing or whole-genome sequencing.14

Epirogenetic mechanisms unrelated to altered DNA sequences that may affect epileptogenesis include transcriptional or post-transcriptional regulation. The pathogenesis of different types of epilepsy involves many important biological pathways, some of which have been shown to be regulated by microRNAs (miRNAs), small non-coding RNA of about 22 nt in length, which are able to regulate the stability of several

https://doi.org/10.1016/j.omtn.2018.09.008.

*These authors contributed equally to this work.

Correspondence: Gloria Bertoli, Institute of Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR), Via F. Cervi 93, 20090 Segrate-Milan, Italy.
E-mail: gloria.bertoli@ibfm.cnr.it

Correspondence: Antonio Gambardella, Institute of Neurology, Department of Medical and Surgical Sciences, University "Magna Graecia," Germaneto, 88100 Catanzaro, Italy.
E-mail: a.gambardella@unicz.it
mRNAs by binding to their complementary sequence at the 3’ UTR of a coding mRNA. miRNA works in a particular way for activity-dependent regulation of mRNA stability and translation. Previous studies have focused on the regulations of miRNA on its target genes, and some studies analyzed the effects of the altered expression of single miRNA, increasing or decreasing miRNA levels in mouse and rat models, and observing the amelioration of the pathological features of epilepsy.

The alteration in the expression levels of specific miRNAs has been described as a possible cause in the onset of different pathologies, from cancer to brain pathologies, such as Parkinson’s disease, Alzheimer’s disease (AD), or other neurodegenerative diseases. In epilepsy, several studies showed an alteration of global miRNA expression profiles in a variety of animal models and humans. Specific miRNAs in brain tissue have been linked to seizure-induced neuronal death or neuroprotection. Components of the miRNA biogenesis pathway that have been found to be altered in brain tissue from epilepsy patients result in select changes to miRNAs regulating neuronal microstructure, cell death, inflammation, and apoptosis. Over the past 5 years, several target studies and genome-wide miRNA expression-profiling studies have identified over 100 different miRNAs in epilepsy patients or animal models, and they have provided compelling evidence that epilepsy is associated with widespread changes of miRNA expression. The first study on miRNA in human epilepsy was published in 2010 and reported an increase in hippocampal levels of miR-146a, an miRNA linked to the control of the pathological features of epilepsy.

Given that one miRNA is able to regulate several target genes belonging to different functional pathways, in this review, we highlight the role of miRNAs in controlling epilepsy functional hallmarks starting from the analysis of miRNA profiles of focal epilepsy animal models. We then tried to assess those miRNAs found commonly altered in tissues from animal models and in human focal epilepsy tissues, and we discussed their role in functional pathways altered in temporal lobe epilepsy (TLE) (Figure 1). As circulating miRNAs could become the targets of therapeutic tools, we then focused on those human circulating miRNAs that, having a main role in the control of specific functional hallmarks associated with focal epilepsy, could become potential pharmacological targets for focal epilepsy (Figure 1).

miRNA Production

miRNA sequence is transcribed by RNA polymerase II (Pol II) as a long primary transcript (pri-miRNA). The majority of miRNAs are located in intronic regions of protein-coding mRNA. As soon as the miRNA is spliced, pri-miRNAs emerge as a long hairpin structure. During the maturation, miRNA loses part of its sequence, being cut by Drosha in the nucleus and DICER complex in the cytoplasm. One strand of the duplex miRNA, the guide strand, is recognized and loaded into the RNA-induced silencing complex (RISC) to elicit its silencing effect. The other strand, the passenger strand (indicated as miRNA*), is usually degraded. Once miRNA recognizes the complementary sequence on the target miRNA (called the seed sequence), it binds to it, leading to miRNA degradation or repression, depending on the level of pairing with the seed sequence (Figure 2).

In mammals, 60% of the miRNAs have a known seed sequence for miRNA binding; thus, miRNAs play an essential role in controlling all the cellular processes. In the brain, miRNAs are particularly abundant and control neurogenesis. In Dicer−/− mouse model, the biogenesis of miRNA is blocked, leading to neuronal loss and premature animal death.

Tissue-Associated and Circulating miRNAs in Focal TLE Animal Models

Some epileptic models have been developed to understand the onset and development of the pathology. Initially, to study epilepsy, simple acute seizure models were developed, as those obtained by pentylene-tetrazol or the volatile chemoconvulsant flurothyol treatment to induce seizures, or maximal electroshock seizure models, but these models failed to mimic the spontaneous onset of seizures, typical of epilepsy.

Epilepsy has been studied in several organisms, starting from the simpler (i.e., Drosophila melanogaster, Caenorhabditis elegans, and Danio rerio) to non-human primates. Nowadays, the most commonly used rodent models to study epilepsy are Rattus norvegicus and Mus musculus. The use of these animals has been helpful to generate genetic models of epilepsy. These models have been...
developed from the observation that single-gene mutations could be the cause of epileptic disease, such as mutation in ion (voltage-gated sodium channels, potassium channels, or calcium channels) and neurotransmitter receptor. In the last case, epilepsy is a comorbid phenotype caused by other pathologies, such as AD, autism, or other neurological disorders.

More recently, other rodent models have been developed to study the status epilepticus (SE), which is an episode of prolonged seizures generated by an initial precipitant injury, affecting the hippocampus and/or the temporal lobe. These animal models were generated to mimic TLE, the most common form of epilepsy that displays a clinical history including an onset injury, a pre-epileptic latent period before the manifestation of spontaneous seizures, a chronic clinical manifestation, and the typical histopathological neuronal changes of human TLE. No animal model has been proposed until now to describe the development of non-focal epilepsy, possibly because the origin of this form of epilepsy is not completely understood. To generate TLE-associated status, the main models of acquired epilepsy are due to intracerebral or systemic injection of drugs (such as pilocarpine, kainic acid [KA], or bicuculine) or of toxins (tetanus toxins) or mimicking the etiology due to febrile seizures by hyperthermia treatment, sustained electrical stimulation, or ischemia. Hyperthermia is a good model to mimic TLE, while the treatment with KA (an agonist of ionotropic glutamate receptor) or pilocarpine (an agonist of cholinergic muscarinic receptor) is the most commonly used

Figure 1. Flowchart
Flowchart representing the logic flux of the analysis for the identification of animal-derived (A) and human (B) miRNAs with a main role in epilepsy. The selection criteria in the (A) and (B) approaches are indicated in the ovals. The horseshoe symbol indicates selecting miRNAs in common among. Coherent pattern means selecting an miRNA only if the miRNA has constantly been found with an upregulated or downregulated pattern. Circulating miRNAs previously found with therapeutic effect are indicated (‘+’) and the other circulating miRNAs are also indicated (‘').

Molecular Therapy: Nucleic Acids Vol. 13 December 2018 277
model, presenting a histopathological profile similar to that observed in mesial TLE patients.45

The research of miRNAs in biofluids of animal models of epilepsy could be helpful in order to identify new, specific, sensitive, reproducible, predictive, and accurate biomarkers and to develop new, non-invasive, standardized, cost-affordable, and easy-to-perform detection assay for the differential diagnosis of TLE.46 We have found a few publications that propose a diagnostic signature of circulating miRNAs obtained by the study of animal models (i.e., Gorter et al.32 and Hu et al.47), while several single miRNAs have been shown to possess diagnostic properties (i.e., Liu et al.42). Some papers discussed the miRNA profile of brain tissues of focal TLE animal models (i.e., Hu et al.47 and Li et al.48) and also presented data regarding circulating miRNAs (i.e., Gorter et al.32). These miRNAs are summarized in Table 1, grouped for each animal model. Some papers propose a single miRNA as a possible epilepsy biomarker, but without presenting an miRNA profile able to describe the pathology.49

In 2014, three papers analyzed the miRNA profile of brain tissue extracted from two different rat epileptic models. High-throughput sequencing analysis of rat hippocampus generated by amygdala stimulation revealed that 7 miRNAs were differentially expressed in TLE models with respect to a non-stimulated animal model48 (Table 1). In particular, all these miRNAs were upregulated in TLE, except miR-296-5p, which was downregulated. These miRNAs were validated by RT-PCR. The analysis of the functional role of these miRNAs in epileptic hippocampus revealed that, in chronic TLE, the main

---

**Figure 2. miRNA Biogenesis**

The life of an miRNA begins in the nucleus, where RNA polymerase II (Pol II) transcribes the whole RNA along with miRNA. The long primary miRNA (pri-miRNA) (approximately 1 kb) with its hairpin structure is processed by the Drosha-DGCR8 complex. The microprocessor complex, formed by Drosha and its cofactor DGCR8, lead to the maturation of the pri-miR into precursor miRNA (pre-miRNA). The RNase activity of Drosha removes the stem loop structure, releasing a small hairpin RNA of approximately 65 bp. Several other proteins collaborate with the microprocessor to guide the correct maturation of the pri-miRNA (p53, SMAD1-3, p68, and TDP43). After Drosha processing, pre-miRNAs are exported into the cytoplasm by the transport complex formed by Exportin 5 and RAN-GTP. Once the complex is translocated into the cytoplasm, GTP is hydrolyzed to GDP, leading to complex disassembly. In the cytoplasm, another RNase guides the maturation of pre-miRNA into the duplex form, i.e., Dicer. Dicer interacts with the double-strand hairpin structure of the cytosolic pre-miRNA and, in collaboration with TAR RNA-binding protein, cleaves the RNA duplex; further, the mature miRNA is loaded directly into the RNA-induced silencing complex (RISC), whereas the passenger miRNA is usually degraded. The RISC complex needs the help of two heat shock cognate proteins (Hsc70 and 90) that, using ATP, mediate the opening of the Argonaute (AGO) protein to receive the miRNA duplex. The RISC receives the duplex, unwinds it, and degrades the passenger miRNA. The pairing between the RISC-mature miRNA and the seed sequence on the target mRNA determines mRNA degradation or mRNA repression.38
Table 1. Summary of miRNAs Involved in Focal TLE, as Obtained by the Study of the miRNA Profiles in Tissues and/or Biofluids of Three Different Animal Models

| Epilepsy Model | Tissue | Up miRNA | Down miRNA | Differential Diagnosis | Reference |
|---------------|--------|----------|------------|------------------------|-----------|
| Amygdala electric stimulation | plasma | miR-21-5p, -142-5p, -146-5p | miR-296-5p | focal TLE | 66 |
| PI rat model | H | miR-23a, -146a, and -212* | miR-21-5p, -132-3p, -212, -145, -150, -151, -196b, -199a, -213, -375 | acute + latent miR-145 chronic miR-138 | 32 |
| KA-induced rat model | H | miR-23a, -27a, -31, -34a, -146a, -152, -203, -210, -211 | miR-219a, -33, -135b, -136, -138*, -144, -153, -190, -296*, -301a, -325-5p, -380, -542-3p, -542-5p, -543 | focal TLE | 15 |
| Blood | H | miR-22-29a, miR-125a | miR-17-3p, miR-99b-3p, miR-182, miR-193, miR-196, miR-197, miR-199a, -200a, -203, -212, -221, -222, -223, -267-3p, -297c-5p, -455-5p, -466f-5p, -467-3p, -467-5p, -468-5p, -469-3p, -469-5p | focal TLE | 47 |

H, hippocampus; DG, dentate gyrus; up miRNAs, upregulated miRNAs; down miRNAs, downregulated miRNAs; PI, pilocarpine-induced; KA, kainic acid.

function controlled by these miRNAs is apoptosis, which is observed as a neuronal loss induced by TLE.

The second paper32 presented the analysis of rat brain hippocampal and dentate gyrus (DG) tissues from electrically induced SE compared to control tissues. This work revealed that several miRNAs were altered at different time points (day 1 and day 7 to simulate acute phase and 3 months after seizures at latent stage). In particular, miR-21 was upregulated in both acute and latent stages; miR-143, miR-23a, and miR-27a were upregulated in both latent and chronic stages in the CA1 region of the hippocampus (Table 1). In DG, 4 miRNAs were upregulated at all time points: miR-132, -132*, -21, and -212. miR-142-5P was upregulated in acute and latent stages, but not in chronic phase, while three miRNAs were upregulated only in chronic and latent phases: miR-23a, -146a, and -212*. miR-223 was upregulated only in acute and chronic phases. In the same paper, plasma miRNA analysis was performed. It confirmed that miR-21-5p, -146-5p, and miR-142-5p were upregulated; in particular, miR-21-5p increased significantly at 1 week post-SE, while miR-146a-5p showed an increased expression 3–4 months after SE and not 1 week after SE, as observed in the tissues. miR-142-5p was increased in plasma 24 hr and not 1 week after SE. Regarding the role controlled by these miRNAs in the epileptic models after 1 week from SE, the main functions are those related to the inflammatory process (transforming growth factor β [TGF-β] signaling and Toll-like and interleukin-1 receptor signaling). The inflammatory pathway is controlled by miR-19b, miR-20b, miR-21, and miR-146a, which are all upregulated, and miR-33, which is downregulated. In the tissues, miR-21 and miR-21* are the most upregulated miRNAs after 1 week of SE in all the rat brain tissues. Also, these miRNAs seem to be involved in the regulation of inflammatory process, associated with Toll-like receptor signaling.

The third paper47 presented the results of the analysis of rat hippocampus from a pilocarpine-induced epileptic model; miRNA array profiling revealed 19 upregulated and 7 downregulated miRNAs (Table 1). The comparative analysis of these miRNAs in the hippocampus from this epilepsy model showed that miR-21 was decreased...
in hippocampal tissue, while miR-22, miR-34a, and miR-125a-5p were increased. This paper presented also the results of miRNA profiling in peripheral blood samples of the same epileptic model. Some miRNAs were investigated; miR-21-5p was decreased, while miR-22, miR-34a, and miR-125a were confirmed to be increased. The deregulated miRNAs were predicted to control the mitogen-activated protein kinase (MAPK)-signaling pathway, TGF-β-signaling pathway, long-term potentiation pathway, tight junction pathway, glycan structure-biosynthesis 1, and axon guidance.57

In another paper, high-throughput miRNA profiling was used to analyze differentially expressed miRNAs in rat hippocampus 24 hr after amygdala electric stimulation50 (Table 1). Five miRNAs were increased in 1 week, while only miR-99b-3p was decreased 3 weeks after SE. The expression of miR-365-5p and miR-99b-3p correlated with neuronal apoptosis observed in SE tissues.50

The analysis of the DG of the amygdala in electrically stimulated rats revealed that 9 miRNAs were upregulated, while 57 miRNAs were downregulated.51 The miRNAs with the highest downregulation were miR-7a-5p, miR-187-3p, and miR-551b-3p, while those with the highest increase were miR-21-5p, miR-212-3p, and miR-132-3p. The analysis of potential miRNA targets revealed that several biological functions could be affected, such as transcription, response to wounding, apoptosis, cell proliferation, and immune response.31

The miRNA expression profile analysis of the rat models of SE and TLE induced by pilocarpine treatment revealed that 9 miRNAs were upregulated and 15 were downregulated18 (Table 1). Among the others, miR-34a was significantly upregulated.18

In another pilocarpine-induced epilepsy mouse model on hippocampus, miRNA profile revealed that, at a later time (28 days after the induction of SE with pilocarpine treatment), 51 miRNAs were significantly deregulated. In particular, 22 miRNAs were upregulated while 29 were downregulated51 (Table 1).

DG and hippocampus tissues isolated from a KA mouse model or saline-injected mouse were subjected to multi-omics profile.52,53 Among the 189 dysregulated miRNAs,53 the authors highlighted the upregulation of 15 hippocampal miRNAs, with an enrichment of brain-specific miRNAs (Table 1). In another publication,54 CA3 regions from control or KA-treated animals were isolated and subjected to miRNA profile. The analysis revealed an increase of 25 miRNAs in epileptic models versus control (Table 1). In Pichardo-Casas et al.,55 KA-treated hippocampus was analyzed for specific miRNAs, and the authors identified a general reduction of all considered miRNAs, with a significant reduction in miR-145 expression. In Jimenez-Mateos et al.,56 the miRNA profile was extracted from the ipsilateral CA3 subfield 24 hr after focal-onset SE in KA animal models, and 45 miRNAs were found altered in SE versus controls (Table 1).

Regarding the miRNA profile of the KA mouse or rat model of epilepsy, no paper actually exists with an miRNA profiling of epilepsy-associated plasma or serum. Only one paper presented the miRNA profile for brain ischemia, hemorrhage, and KA-induced seizure tissues and blood;57 but, in this paper, the list of all the miRNA specifically altered in the blood of SE models versus control animals is not specifically reported.

All the results highlight the importance of miRNA in the epilepsy phenotype, but a general agreement on a few common groups of miRNAs as possible diagnostic or prognostic biomarkers of epilepsy is still lacking. By comparing the lists of altered miRNAs in all the analyzed papers, we sum up with the tissue-associated miRNAs with a coherent pattern of expression in two models of epilepsy (with coherent we mean those miRNAs that are increased or decreased in the same way in two different epilepsy models), representing a core list of 20 possible epilepsy-associated miRNAs altered in at least 2 of 3 animal models of chronic epilepsy: miR-23a, miR-27a, miR-31, miR-99a, miR-125b-5p, miR-129-5p, miR-142-5p, miR-146a, miR-212-3p, and miR-375 all upregulated; miR-10b, miR-21, miR-29a, miR-138, miR-153, miR-181c, miR-187-3p, miR-330-3p, and miR-551b-3p all downregulated.

**Translation of miRNAs Identified in TLE Animal Models to Human TLE**

Analyzing the literature to identify all the publications on whole miRNA profiling on human epileptic tissues (hippocampus or DG), we identified only one new recent paper that proposes the whole miRNA profile of human hippocampus of TLE subjects.58 Considering the 20 tissue-isolated miRNAs in common between at least two TLE animal models obtained by an analysis of Table 1 (namely, miR-23a, miR-27a, miR-31, miR-99a, miR-125b-5p, miR-129-5p, miR-132-5p, miR-142-5p, miR-146a, miR-212-3p, and miR-375 all upregulated; miR-10b, miR-21, miR-29a, miR-138, miR-153, miR-181c, miR-187-3p, miR-330-3p, and miR-551b-3p all downregulated), we found some present in the profiles of human epileptic tissue. In particular, we found 4 miRNAs that are in common with the miRNA hippocampus profile of human TLE subjects.59 Following the new annotation suggested by the database http://mirgenedb.org/,59 the four miRNAs are Hsa-miR-132-P1, Hsa-miR-142-P1-v1_5p, Hsa-miR-146-P1_5p, and Hsa-miR-138-P1_5p.

A recent publication by Korotkov60 proposed a meta-analytic approach to identify unique miRNA profiles by comparison of three post-epileptic seizure models. In our approach, Korotkov’s analysis includes electrical stimulation, pilocarpine, and KA models. The authors compared profiles obtained by their analyses with the miRNA profile of human TLE with hippocampal sclerosis, which instead was not included in our study. The Korotkov analyses also considered different stages of epileptogenesis in animal models, while we focused on miRNA profiles of the latent and chronic epileptic statuses of animal models, which, in our opinion, are more similar to human disease when it is diagnosed. Some miRNAs of latent and chronic stages described by Korotkov have also been found in our analysis (i.e., miR-23a and miR-146a-5p among the upregulated miRNAs and miR-551b-3p among the downregulated miRNAs).
1,077 pathways derived from the Reactome, BioCarta, and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. The enrichment for each miRNA was evaluated using the Fisher's exact test between miRNA targets and the selected 1,077 pathways. We considered a pathway to be enriched if the p value was <0.01; p values were adjusted using the Benjamini-Hochberg procedure for multiple testing correction. The association between miRNA and its target gene was confirmed using experimentally validated databases, such as miRTAR, miRWalk, and miRTarBase. An R package, SpidermiR, was used to integrate the data. The only miRNAs that control functional pathways, in a statistically significant way, are Hsa-miR-132-P1, Hsa-miR-138-P1_5p, Hsa-miR-142-P1-v1_5p, and Hsa-miR-146-P1_5p (Table 2).

Among the pathways controlled by these four miRNAs, there are (1) cell cycle, proliferation, and apoptosis; (2) neuroinflammation; (3) gene expression; and (4) tissue remodeling (Table 2).

(1) Cell cycle, proliferation, and apoptosis. Hsa-miR-132-P1 has been already studied in cancer, playing a role in the control of proliferation, apoptosis, and epilepsy-associated inflammation. In TLE, miR-146 upregulation is usually associated with not only neuroinflammation but also the suppression of proliferation and decrease of vascular endothelial growth factor (VEGF) expression and vasculogenesis. It has been already reported that, in epilepsy, a loss of neurons and an increase in inflammation are among the main histopathological features.

(2) Neuroinflammation. Several pro-inflammatory cytokines increase during epilepsy or after an epileptic event, and, as a consequence, their related miRNAs are also affected. Regarding miR-146a-5p, previous publications have demonstrated it to play a role in the increase of IL-1beta and tumor necrosis factor alpha (TNF-α), being upregulated in hippocampal astrocytes of epileptic rat models and in human brain tissues. It has been suggested that the upregulation of miR-146a-5p could represent an attempt of the astrocytes to modulate and reduce inflammatory response due to IL-1b, perhaps by modulating IL-1R1-associated protein kinase-1 and -2 (IRAK1 and IRAK2) and TNF receptor-associated factor 6 (TRAF6). In rodents, pharmacological treatment with a blockade of IL-1b synthesis reduced seizure, decreasing the inflammation associated with SE. Thus, miR-146a-5p could be proposed as a possible target to inhibit epilepsy-associated neuroinflammation.

(3 and 4) Gene expression and tissue remodeling. The control of miRNAs on gene expression could lead to different functional outcomes. A clear role of hsa-miR-132-P1 in protein kinase-1 and -2 (IRAK1 and IRAK2) and TNF receptor-associated factor 6 (TRAF6). In rodents, pharmacological treatment with a blockade of IL-1b synthesis reduced seizure, decreasing the inflammation associated with SE. Thus, miR-146a-5p could be proposed as a possible target to inhibit epilepsy-associated neuroinflammation.

### Table 2. Summary of Genes and Functional Pathways that Are Targets of Epilepsy-Associated miRNA in Common among at Least Two Temporal Lobe Epilepsy Animal Models and TLE Human Tissues, with Coherent Behavior

| miRNA          | Functional Pathway                        | Target Genes in the Functional Pathway                                                                 |
|----------------|-------------------------------------------|---------------------------------------------------------------------------------------------------------|
| Hsa-miR-132-P1 | cell cycle, proliferation, apoptosis      | CDKN1A, PSMA2, PSMD12, RB1, CCNA2, CCNB1, MAPK1, CDKN1A, CRK, HBEGR, FOXO1                           |
|                | neuroinflammation                         | NGF signaling: CDKN1A, CRK, ECT2, FOXO1, IRAK1, MEF2A, MAPK1, RTN4, MAP3K3, BDNF, IRAK4                |
|                |                                            | PDGF signaling: CDKN1A, CRK, FOXO1, MAPK1, RAS1, THBS1                                                  |
|                |                                            | ILS signaling: CRK, IRAK1, MAP3K3, IRAK4, MAPK1                                                        |
|                | gene expression                           | MAPK signaling: CDKN1A, CRK, FOXO1, MAPK1, RAS1, IRAK1, MEF2A, IRAK4                                  |
|                | tissue remodeling                         | extracellular signaling: SEC61A3, RPSA, RPL7, RPS5, SSR3                                              |
| Hsa-miR-138-P1_5p | cell cycle, proliferation, apoptosis     | HIF1A, NFKB1, RARA, CASP3, CCND1, CDH1, CEBPA, PAPARG                                                |
|                | focal adhesion                            | IGF1R, PTK2, AKT1, CCND1                                                                             |
| Hsa-miR-142-P1-v1_5p | cell cycle, proliferation, apoptosis | HIF1A, TGFBR2, TGFBR2, SMAD3, PTEN, RAC1                                                               |
|                | neuroinflammation                         | RARA, CEBPA, EIF4EBP1, AKT1, NFKB1, CCND1                                                            |
|                | focal adhesion                            | IGF1R, PTK2, AKT1, RELN, ROCK2, CCND1, CCND3                                                          |
|                | tissue remodeling                         | CDH2, AKT1, FABP4, RHOC, LPL, PAPARG, PTK2, CCND3, ROCK2                                              |
| Hsa-miR-146-P1_5p | cell cycle, proliferation, apoptosis     | CD40LG, CFH, FADD, Icam1, IFI27, IRF7, IGF15, KIF22, MX2, OAS1, OSBP1A, RAC1, S1K8                  |
|                | neuroinflammation                         | ILS signaling: IRAK1, IRAK2, STAT1                                                                  |
|                |                                            | immune response: TLR2, TLR4, TRAF6                                                                  |
|                | tissue remodeling                         | extracellular signaling: IFIT1, IFIT3, IFITM1, IFITM3, ITGB2                                        |
In animal models, the main miRNA isolated in the blood of at the main problem is the standardization of biomarker analysis in epilepsy without proposing any miRNA profile related to the disease. Authors identified miR-19b-3p as significantly downregulated in epilepsy versus control, while miR-451a was significantly higher in TLE versus control samples. Receiver operator characteristic (ROC) analysis revealed that miR-19b-3p shows a good performance in the diagnosis of epilepsy (area under the curve [AUC] 0.73) and that the combination of miR-19a-3p and miR-451a has the best AUC value (0.82). In the third paper, serum profiles of the miRNA of 30 epileptic patients versus 30 healthy control were analyzed. Among 2,578 serum miRNAs analyzed with the Illumina platform, the authors found that 4 miRNAs were significantly upregulated (let-7d-5p, miR-106b-5p, miR-130a-3p, and miR-146a-5p), whereas 6 miRNAs (miR-15a-5p, -144-5p, -181c-5p, -194-5p, -889-3p, and novel-mir-96) were downregulated. The RT-PCR validation phase on 30 epileptic versus 30 healthy subject serum profiles revealed that miR-15a-5p, miR-194-5p, and miR-96 were downregulated, while let-7d-5p, miR-106b-5p, -130a-3p, and -146a-5p were increased in epileptic versus normal subjects. The ROC analysis on 112 patients versus 112 healthy controls revealed that 6 miRNAs could be proposed as diagnostic biomarkers of epilepsy (let-7d-5p, miR-15a-5p, miR-106b-5p, miR-130a-3p, and miR-146a-5p, and miR-194-5p) and that serum miR-106b-5p is the best diagnostic circulating miRNA for epilepsy, with 80.3% sensitivity and 81.2% specificity. The authors proposed miR-106b-5p as the best diagnostic circulating miRNA for epilepsy diagnosis.

In the fourth paper, plasma miRNAs were analyzed, and decreased expression of miR-134a was proposed as a circulating biomarker of mesial TLE (MTLE) validated on a cohort of 65 MTLE and 83 controls. In serum, four epilepsy-associated miRNAs (miR-106b, miR-146b, miR-194-5p, and miR-301a) have been validated by RT-PCR in 90 epileptic subjects against 90 control subjects in the fifth paper. The authors found that miR-106b, miR-146b, and miR-301a significantly increased while miR-194-5p decreased in TLE samples. Moreover, the use of miR-106b and miR-146b has been proposed as a two-miRNA signature with diagnostic ability.

Plasma miRNAs have been isolated from exosomes as well. Among the 6 differentially expressed miRNAs in human plasmatic exosomes among epileptic and healthy subjects, miR-3613 emerges as the best diagnostic molecule (AUC = 0.8444).

| Human Biofluid | Circulating miRNA | Aim | Reference |
|---------------|-------------------|-----|-----------|
| CSF           | miR-19b-3p (down); miR-451a (up) | TLE diagnosis (AUC = 0.82) | 87 |
| Serum         | let-7d-5p, miR-106b-5p, -130a-3p, -146a-5p (up); miR-15a-5p, -194a-5p (down) | TLE diagnosis (AUC all = 0.88) (AUC miR-106b-5p = 0.882) | 88 |
| Plasma        | miR-34a (down) | mesial TLE diagnosis (AUC = 0.671) | 90 |
| Serum         | miR-106b-5p, -146a (up) | TLE diagnosis (AUC = 0.887) | 10 |
| Plasma exosomes | miR-3613-5p (up); miR-197-5p, miR-4322, miR-4668-5p, miR-6781-5p, miR-8071 (down) | TLE diagnosis (AUC for miR-3613-5p = 0.8444) | 91 |

Circulating miRNA in Human Epilepsy

One interesting feature of miRNAs is that they can be secreted and found in various human biofluids (lacrime, milk, serum, plasma, saliva, and urine) under both physiological and pathological conditions. This feature makes miRNAs a promising molecule for diagnosis, prognosis, or the development of new therapeutic tools. Although the miRNA expression level in biofluids is not abundant, several commercial kits allow their isolation, identification, and amplification by real-time qPCR or next-generation sequencing (NGS) approaches on a low-cost basis. The main problem is the method for the selection of the group of epilepsy-associated miRNAs.

In animal models, the main miRNA isolated in the blood of at the least two different TLE models is miR-21-5p. Looking for “circulating diagnostic miRNA in human epilepsy,” we found only 6 papers in PubMed (November 2017). To identify a reliable diagnostic biomarker able to identify the pathology, we analyzed those 6 publications and the results are presented here (Table 3).

One paper was excluded because it describes the procedures for the standardization of biomarker analysis in epilepsy without proposing any miRNA profile related to the disease.

In the second paper, the circulation of the miRNA profile in humans was analyzed in cerebrospinal fluid (CSF), this fluid being in close contact with the brain tissue involved in the pathology. CSFs from 15 TLE patients were compared to those of 15 healthy subjects. The authors identified miR-19b-3p as significantly downregulated in epilepsy versus control, while miR-451a was significantly higher in TLE versus control samples. Receiver operator characteristic (ROC) analysis revealed that miR-19b-3p shows a good performance in the diagnosis of epilepsy (area under the curve [AUC] 0.73) and that the combination of miR-19a-3p and miR-451a has the best AUC value (0.82). In the third paper, serum profiles of the miRNA of 30 epileptic patients versus 30 healthy control were analyzed. Among 2,578 serum miRNAs analyzed with the Illumina platform, the authors found that 4 miRNAs were significantly upregulated (let-7d-5p, miR-106b-5p, miR-130a-3p, and miR-146a-5p), whereas 6 miRNAs (miR-15a-5p, -144-5p, -181c-5p, -194-5p, -889-3p, and novel-mir-96) were downregulated. The RT-PCR validation phase on 30 epileptic versus 30 healthy subject serum profiles revealed that miR-15a-5p, miR-194-5p, and miR-96 were downregulated, while let-7d-5p, miR-106b-5p, -130a-3p, and -146a-5p were increased in epileptic versus normal subjects. The ROC analysis on 112 patients versus 112 healthy controls revealed that 6 miRNAs could be proposed as diagnostic biomarkers of epilepsy (let-7d-5p, miR-15a-5p, miR-106b-5p, miR-130a-3p, and miR-146a-5p, and miR-194-5p) and that serum miR-106b-5p is the best diagnostic circulating miRNA for epilepsy, with 80.3% sensitivity and 81.2% specificity. The authors proposed miR-106b-5p as the best diagnostic circulating miRNA for epilepsy diagnosis.

In the fourth paper, plasma miRNAs were analyzed, and decreased expression of miR-134a was proposed as a circulating biomarker of mesial TLE (MTLE) validated on a cohort of 65 MTLE and 83 controls. In serum, four epilepsy-associated miRNAs (miR-106b, miR-146b, miR-194-5p, and miR-301a) have been validated by RT-PCR in 90 epileptic subjects against 90 control subjects in the fifth paper. The authors found that miR-106b, miR-146b, and miR-301a significantly increased while miR-194-5p decreased in TLE samples. Moreover, the use of miR-106b and miR-146b has been proposed as a two-miRNA signature with diagnostic ability.

Plasma miRNAs have been isolated from exosomes as well. Among the 6 differentially expressed miRNAs in human plasmatic exosomes among epileptic and healthy subjects, miR-3613 emerges as the best diagnostic molecule (AUC = 0.8444).
In the sixth paper,92 a comparative analysis of circulating miRNAs in epilepsy has been proposed. In recent years, several miRNAs have been proposed as circulating biomarkers, showing dynamic changes of miRNA expression in relation to the history of the pathology. Some miRNAs could be expressed soon after the onset of seizures (i.e., miR-9a-3p), whereas others were expressed only after the chronicization of the disease (i.e., miR-21-5p).92

Considering both animal models and human samples, several inconsistencies emerge among the identified epilepsy-associated circulating miRNAs, and a unique miRNA signature associated with epilepsy is not detectable. In particular, when a comparison between miRNA profiles obtained from bioloids in an animal model and the circulating miRNA profile of human epilepsy is performed, only Hsa-miR-146-P1_5p and Hsa-miR-34-P1 are commonly present in the plasma of epilepsy animal models32,55 and in human serum samples.88,90 Circulating Hsa-miR-146-P1_5p has already been associated with human TLE by several papers (i.e., Korotkov), and Hsa-miR-34-P1 could potentially become a new diagnostic circulating biomarker of epilepsy. The limited overlap among human and mouse model circulating miRNA profiles could be due to the differences of the species used for animal models (rat versus mouse) and human pathology, different time points during pathology development in animal models, the different techniques used for epilepsy generation (electric stimulus versus pilocarpine injection versus KA injection), or the different methods used for miRNA analysis (NGS or RT-PCR).

To understand which miRNAs have a key role to play in epilepsy development, we evaluated the role of all the 15 circulating miRNAs described in Table 3, with an in silico approach in relation to their role in epileptic hallmarks, with epileptic hallmarks being the main biological pathways affected in epilepsy.88,90 We consider epilepsy hallmarks all the pathophysiological processes that are altered in epilepsy, giving rise to spontaneous seizures, such as those reported in Brennan and Henshall16 and Shao and Chen:92 neuroinflammation, neurodegeneration, neurogenesis, gene expression, oxidative response, neuronal plasticity, tissue remodeling, circadian rhythm, and drug resistance.16

**TLE-Associated Circulating miRNAs Control Cell Proliferation and Apoptosis, Brain Tissue Remodeling, and Neuroinflammation**

Some papers have described the role of miRNAs on epileptic hallmarks (i.e., Brennan and Henshall16) but without analyzing in detail the molecular pathway and the genes within those pathways, which are targets of the identified miRNAs by an in silico approach. In other recent reviews (i.e., Henshall), a detailed description of the use of miRNAs as potential therapeutic tools is offered. In our approach, we used bioinformatics tools to identify miRNAs with a major role in the control of functions altered in epilepsy while also considering miRNAs as potential therapeutic molecules. In particular, we focused mainly on the use of those miRNAs that we selected with our approach as potential therapeutic tools.

To identify a small number of miRNAs with a key role in epilepsy development, we evaluated the role of all the 15 circulating miRNAs in Table 3 (let-7d-5p, miR-15a-5p, -19b-3p, -34a, -106b-5p, -130a-3p, -146a-5p, -194a-5p, -197-5p, -451a, -3613-5p, -4322, -4668-5p, -6781-5p, and -8071) through a Pathway Enrichment Analysis, as described previously, involving the identification of a group of pathways significantly enriched with miRNA targets.

Figure 3 shows pathways enriched with miRNA-validated targets for 8 of the 15 miRNAs of Table 3, namely, let-7d-5p, miR-15a-5p, miR-19b-3p, miR-34a, miR-106b-5p, miR-130a-3p, miR-146a-5p, and miR-451. Indeed, no validated miRNA targets were found for miR-194a-5p, -451a, -3613-5p, -4322, -4668-5p, -6781-5p, and -8071.

Among the most enriched pathways identified, there were the following: immune system, cell cycle, apoptosis, and neurotrophin-signaling pathway (Figure 3).

Focusing on the 8 human circulating epilepsy-associated miRNAs, we analyzed their possible role in epilepsy-associated cellular functions.16 From our analysis, the known, major physiological processes altered in TLE include the following (Figure 3):

1. **Neuroinflammation with the involvement of microglia**, which was called “immune system” in in silico analysis (Figure 3 in brown gradation). This pathway includes several genes regulated by miR-15a-5p (downregulated), miR-106b-5p, miR-146, and miR-451 (see Table S1). As already seen, several pro-inflammatory cytokines are increased during epilepsy or after an epileptic event. miR-15b-5p has been found to be specifically upregulated in the CSF of subjects who were Alzheimer’s patients,93 correlated to plaque scores. On the contrary, in another pathology, i.e., that of diabetic retinopathy, miR-15a-5p (downregulated), miR-106b, and miR-451 have been proposed as a key regulator of both pro-inflammatory and proangiogenic pathways via the regulation of acid sphingomyelinase (ASM) and VEGF-A.96 In epilepsy, this miRNA has been found to be downregulated, suggesting a possible loss of control over the enzyme ASM, leading to the conversion of sphingomyelin into pro-inflammatory and pro-apoptotic ceramide.97

miR-106b, found upregulated in epilepsy, was described to be involved in AD-associated inflammation.99 As simvastatin has been proposed as a possible anti-inflammatory and anti-apoptotic drug
in AD, recently statins also have been tried as potential anti-seizure drugs, highlighting a possible protective, anti-inflammatory mechanism. Also miR-451, involved in the maintenance of the inflammatory status in several brain pathologies (i.e., Churov et al.), has been proposed as a potential target of several statins.

Regarding miR-146, we have already described its possible role in neuroinflammation.

Some papers described the upregulation of miR-451 in TLE and associated it with inflammation in the brain (i.e., Cogswell et al.).
(2) Neurogenesis, cell cycle control, and cell proliferation, called “cell cycle” in in silico analysis (Figure 3 in purple gradation). This pathway includes all those genes involved in neuronal cell proliferation and differentiation, which are controlled by miR-15a-5p, miR-34a, miR-106b-5p, and miR-451 (see Table S2).

In epilepsy, the observed downregulation of miR-15a-5p could lead to the reducing of its control activity on its targets, including ubiquitin ligase FBXW7 that destabilizes Cyclin E, leading to the block of the cell cycle in the S phase. This could reflect partially the inhibition of neurogenesis, which, with the parallel increase of neuronal apoptosis, leads to the neuronal loss observed in epileptic subjects.

Regarding a possible role of miR-34a in neurogenesis, it has been recently demonstrated that the miR-34/449 family is a key regulator of mitotic spindle orientation during cortex development. Moreover, miR-34 family members are the main upregulated miRNAs in differentiated neurons, and they have a role in the control of cell cycle and the blocking of apoptosis, suggesting that the observed downregulation of miR-34a in epilepsy could lead to cell cycle block, apoptosis activation, and neuronal loss.

Also in the rat model of epilepsy induced by electric stimulation, miR-106b-5p has been reported to be upregulated in the early phase, suggesting a potential role of this miRNA in the induction of neuronal cell cycle block and neuronal apoptosis.

Regarding miR-146, we have already described its possible role in the control of cell proliferation.

(3) Apoptosis (Figure 3 in black gradation). This pathway includes all genes involved in pro- or anti-apoptotic signaling, which are validated targets of miR-15a-5p (downregulated), miR-106b-5p, miR-146, and miR-451 (see Table S3).

The main role of miR-15a-5p in the brain has been described as an ischemic modulator. After ischemic brain injury, miR-15a/16 cluster level is usually increased. It has been observed that the treatment with antagoniR or the genetic loss of this miRNA cluster is able to induce the upregulation of anti-apoptotic proteins (such as Bcl2 and Bcl-w) and suppress pro-inflammatory molecules. It is possible that the observed miR-15a-5p downregulation in epilepsy is mainly caused by the effect of miR-15a-5p decrease on the modulation of neuroinflammatory cytokines.

miR-106b-5p has been predicted to regulate caspase 6 (CASP6) and MAPK-binding protein 1 (MAPKBP1) (inflammation and neuronal apoptosis). SE induces CASP6 expression and activation in rat hippocampus, leading to neuronal apoptosis in different epilepsy models.

The upregulation of miR-146 has been found in several epilepsy models, and it could play a role also in the regulation of neuronal apoptosis.

The upregulation of miR-451 decreases proliferation and promotes apoptosis in other pathologies as well. In CSF, the upregulation of miR-451a has been associated with several CNS pathologies. Regarding the role of miR-451, it is known that this miRNA is able to control the AMPK-mTOR pathway. miR-451 increase, observed in epileptic patients, could modulate autophagy and neuronal loss, as observed in brains after cerebral ischemia.

miRNA-Based Treatment in Epilepsy

miRNA modulation in epileptic animal models could be proposed as a therapeutic tool for modulating the epilepsy phenotype and could be obtained by the administration of synthetic oligonucleotides. These oligonucleotides could encode for the same sequence of the miRNA (miRNA mimic) if it is necessary to increase miRNA sequence as it is downregulated in epilepsy, or the reverse sequence (miRNA inhibitor) if it is necessary to decrease miRNA sequence as it is upregulated in epilepsy. Considering the role of miRNAs in different epilepsy hallmarks, some of the mimics or inhibitor molecules designed on miRNA sequence have been tried as potential therapeutic tools (Figure 3, indicated with a plus sign).

Regarding miRNA mimic or inhibitory synthetic oligonucleotides with potential therapeutic application, several miRNAs considered for the synthetic modulation belong to the class of circulating human TLE miRNAs, as if the modulation of a circulating molecule, used for the communication between cells of the same tissue, could be easier with respect to the modulation of intracellular molecules. In particular, we focused on those 8 of the 15 human circulating epileptic miRNAs that, playing a role in controlling epilepsy hallmark functions, could become the target of new therapies (let-7d-5p, miR-15a-5p, -19b-3p, -34a, -106b-5p, -130a-3p, -146a-5p, -451).

Among these, anti-miR-146a has been administered via intranasal delivery in a pilocarpine-induced TLE mouse model. The percentage of animals with seizure onset was reduced to 6.7%, with a parallel increase in seizure latency and severity. This was possibly caused by the observed decrease in inflammatory modulators, such as nuclear factor kB (NF-kB), TNF-α, IL-1b, and IL-6, as well as IRAK1 and TRAF6. With the same aim, in 2017, Iori et al. utilized the mimic miR-146a injection to block IL-1 receptor/Toll-like receptor (IL-1R/TLR4) molecular pathway, obtaining a reduction of chronic seizure recurrence and preventing the progression of the disease obtained by KA injection. On the contrary, He et al. first demonstrated a significant increase of miR-146a 1 week after the induction of SE in rat by electrical stimulation. They analyzed the effect of antagoniR-146 on both human astrocytoma cell lines and rat epileptic models by injection in the lateral ventricle of the brain. The treatment increased the latency of the first seizures, decreasing the duration and the frequency of the phenomenon.

The differences in the results described in these two publications could be because of different models of epilepsy used. Iori et al. analyzed the modulation of miR-146a in a mouse model obtained by intra-amygdala KA injection. The authors analyzed the effect
of mimic miR-146 pretreatment before the onset of epilepsy or in a mouse model of acquired epilepsy. The authors show that the mimic miR-146 pretreatment decreases hippocampal excitability and acute seizure manifestation, also after KA injection. They hypothesized this occurs by reducing TRAF6 and IRAK2, key proteins for IL-1R1/TLR signaling. Next, the authors studied the effect of miR-146 increase on the acquired epileptic mouse model, and they showed a transient reduction in the number and frequency of seizures. He et al. analyzed the effect of antagoniR-146 on the hippocampus of an electric rat model of epilepsy. In their paper, the authors demonstrated that Complement factor H (CFH) is a direct target that possibly mediates the observed effect of antagoniR-146a. This target gene is described as a critical repressor of the complement and innate immune system, being a specific inhibitor of the C3-to-C3b transition in the complement pathway. It can thus be speculated that, in the initial phases of the disease, the acute phase response signaling is activated (the activation of IL-1R1/TLR signaling), causing the release of numerous proteins in the blood that serve as indicators of an inflammatory state. These indicators activate the complement pathway (second phase) that is required to resolve the cause of inflammation. This two-step process leads to the acquired epilepsy manifestation. We could speculate that in the initial phase, mimic miR-146 is able to silence key transducers of the acute phase response, causing a transient reduction of clinical manifestation of epilepsy, while in the second phase, when the complement system is activated, antagoniR-146 is effective in activating a repressor of the complement system, thus reducing the neuroinflammation associated with the pathology. Recently, a model of activity has been proposed in which the upregulation of miR-146a causes an increase in IL-1b and a parallel decrease of CFH. The increase in IL-1b generates a feedback loop that upregulates miR-146a, which generates the chronicization of the inflammatory state observed in epileptic subjects.

In addition, miR-34a has been proposed as a potential therapeutic target because the administration via the injection of miR-34a antagoniR, reducing its hippocampal levels, has a small modulatory effect on apoptosis, with the exception of severe or moderate SE. Nanoparticles containing miR-34a plasmid have been successfully developed for the modulation of miR-34 within breast cancer treatment. The use of antagoniR of miR-34a has been proposed as a therapeutic approach in a pilocarpine-induced epilepsy rat model, reducing the seizure-induced neuronal cell death at day 7 post-SE. The use of antagoniR-34a in combination with nanoparticles could be proposed as an opportunity for treating epilepsy.

Another research proposed to use mimic miR-19b for the modulation of this miRNA. In particular, the authors incorporated derived microparticles into endothelial cells to modulate the atherosclerosis phenotype in a mouse model. The intravenous injection of the microparticles promoted inflammatory cytokine secretion and macrophage infiltration in perivascular adipose tissues. As miR-19b-3p is downregulated in epileptic subjects, these miR-19b-filled microparticles could be proposed for the treatment of epileptic animal models to decrease the inflammation of epileptic subjects, thus translating this miRNA-based therapy to epileptic patients.

No experiment has been proposed to analyze the in vivo effect of antagoniR-451, let-7d inhibitor, antagoniR-106b, antagoniR-130a, or mimic miR-15a-5p in SE models. These miRNAs could be proposed as possible target molecules for the development of new oligonucleotide-based therapeutic options. No publication is currently available on the role of miR-197-5p, -3613-5p, -4322, -4668-5p, -6781-5p, and -8071 in epilepsy.

Among other antagoniRs analyzed for therapeutic application in epilepsy, antagoniR-134 is one of the most promising miRNAs; a single intracerebroventricular injection of locked nucleic acid (LNA)-antagoniR-134 reduced kainate-induced seizures by 50% and reduced hippocampal cell damage, suggesting the use of this approach in epilepsy. A similar result was obtained by the use of antagoniR-132 in pilocarpine-induced epileptic rats. This treatment reduced SE-associated degeneration of neurons and spontaneous seizures.

Further, miR-184 has been modulated in in vitro experiments, and its overexpression significantly decreased secretion of the pro-inflammatory cytokines IL-6 and IL-1b without affecting mouse neuronal viability.

Until now, no clinical trial has been proposed using miRNA-based treatment as a possible therapeutic option for epilepsy, but some interest is emerging on the role of these molecules during the onset, development, and healing of the disease (ClinicalTrials.gov: NCT02359188).

Conclusions

In this review, we analyzed miRNAs related to epilepsy with diagnostic properties. In particular, we considered all the TLE animal models, and we identified a group of 20 miRNAs (upregulated: miR-23a, -27a, -31, -99a, -125b-5p, -129-5p, -132-3p, -142-p, -146a, -212-3p, and -375; downregulated: miR-10b, -21, -29a, -138, -153, -181c, -187-3p, -330-3p, and -551b-3p) that are commonly altered in at least two different focal TLE animal models. An emerging problem is related to the translation of some of these miRNAs to the human pathology, because there is a poor overlap in the miRNA profiles of human tissues and animal model tissues. Indeed, we found four miRNAs that are common between animal model and human tissue profiles and could be proposed as diagnostic tissue-associated miRNAs (Hsa-miR-132-P1_5p, -138-P1_5p, -142-P1-v1_5p, and -146-P1_5p).

Looking for a small group of TLE-associated circulating miRNAs, we analyzed circulating miRNA profiles of different human body fluids, identifying a group of 15 circulating miRNAs (let-7d-5p, miR-15a-5p, -19b-3p, -34a, -106b-5p, -130a-3p, -146a-5p, -194a-5p, -197-5p, -451a, -3613-5p, -4322, -4668-5p, -6781-5p, and -8071) with potential diagnostic properties in humans. Of these, only miR-146-P1_5p and miR-34-P1 have been found in biofluids of animal models of TLE,
and 8 of the 15 human circulating miRNAs seem to control neuroinflammation, cell proliferation, apoptosis, and brain tissue remodeling, all histopathological features affected in TLE. Until now, miR-194a-5p, -197-5p, -451a, -3613-5p, -4322, -4668-5p, -6781-5p, and -8071 have an unknown role in epilepsy development.

For the development of new therapeutic molecules, theranostic research has selected some miRNAs belonging to the group of TLE-altered tissue miRNAs (i.e., miR-132), although it seems easier for the successful modulation of a circulating molecule (i.e., miR-34 family members or miR-146) with respect to one intracellular miRNA. From our analysis, other miRNAs, especially those circulating (i.e., miR-19b-3p, -34a, and -146a-5p), could emerge as innovative therapeutic molecules for the development of theranostic miRNA-based approaches.

SUPPLEMENTAL INFORMATION
Supplemental Information includes three tables and can be found with this article online at https://doi.org/10.1016/j.omtn.2018.09.008.

AUTHOR CONTRIBUTIONS
C.C. and I.M. made substantial contributions to the conception and design of the work and to data analysis. A.G., G.B., and I.C. made substantial contributions to guiding and revising the work critically for substantial contributions to the conception and design of the work and to data analysis. A.G., G.B., and I.C. made substantial contributions to revising the manuscript, and giving final approval of the version to be published. All authors have read and approved the final manuscript.

CONFLICTS OF INTEREST
The authors have no conflicts of interest.

ACKNOWLEDGMENTS
The authors would like to thank the following for financial support: INTEROMICS flagship project (Interomics PB05), National Research Council CUP Grant B91J2000190001, and the project grant SysBioNet, Italian Roadmap Research Infrastructures 2012.

REFERENCES
1. Megiddo, I., Colson, A., Chisholm, D., Dua, T., Nandi, A., and Laxminarayan, R. (2016). Health and economic benefit of public financing of epilepsy treatment in India: An agent-based simulation model. Epilepsia 57, 464–474.
2. Browne, T., and Holmes, G.L. (2008). Handbook of Epilepsy, Fourth Edition (Philadelphia, PA: Lippincott Williams & Wilkins).
3. Fisher, R.S., Acevedo, C., Arizmangoulou, A., Bogacz, A., Cross, J.H., Elger, C.E., Engel, J., Jr., Forsgren, L., French, J.A., Glynn, M., et al. (2014). ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55, 475–482.
4. Fisher, R.S., Cross, J.H., French, J.A., Higurashi, N., Hirsch, E., Jansen, F.E., Lagae, L., Moshi, S.L., Peltola, J., Routel Perez, E., et al. (2017). Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 58, 522–530.
5. Scheffer, I.E., Berkovic, S., Capovilla, G., Connolly, M.B., French, J., Guillotho, L., Hirsch, E., Jain, S., Mather, G.W., Moshi, S.L., et al. (2017). ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58, 512–521.
6. Fisher, R.S., Cross, J.H., D’Souza, C., French, J.A., Haut, S.R., Higurashi, N., Hirsch, E., Jansen, F.E., Lagae, L., Moshi, S.L., et al. (2017). Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 58, 531–542.
7. Speed, D., O’Brien, T.J., Palotie, A., Shkura, K., Marson, A.G., Balding, D.J., and Johnson, M.R. (2014). Describing the genetic architecture of epilepsy through heritability analysis. Brain 137, 2680–2689.
8. Striano, P., Vari, M.S., Mazzucchetti, C., Verrotti, A., and Zara, F. (2016). Management of genetic epilepsies: From empirical treatment to precision medicine. Pharmacol. Res. 107, 426–429.
9. Meldrum, B.S., and Rogawski, M.A. (2007). Molecular targets for antiepileptic drug development. Neurotherapeutics 4, 8–61.
10. Staley, K. (2015). Molecular mechanisms of epilepsy. Nat. Neurosci. 18, 367–372.
11. Henshall, D.C., Hamer, H.M., Pastorik, R., Goldstein, D.B., Kjems, J., Prehn, J.H.M., Schorge, S., Lamotttke, K., and Rosemon, F. (2016). MicroRNAs in epilepsy: pathophysiology and clinical utility. Lancet Neurol. 15, 1368–1376.
12. Lerche, H., Shah, M., Beck, H., Noebels, J., Johnston, D., and Vincent, A. (2013). Ion channels in genetic and acquired forms of epilepsy. J. Physiol. 591, 753–764.
13. Pérez-Palma, E., Helbig, I., Klein, K.M., Antilla, V., Horn, H., Reinhailer, E.M., Gormley, P., Ganna, A., Byrnes, A., Perharst, K., et al. (2017). Heterogenous contribution of microdeletions in the development of common generalised and focal epilepsies. J. Med. Genet. 54, 598–606.
14. Chen, T., Giri, M., Xia, Z., Subedi, Y.N., and Li, Y. (2017). Genetic and epigenetic mechanisms of epilepsy: a review. Neurobiol. Dis. Treat. 13, 1841–1859.
15. Wu, X., and Bartel, D.P. (2017). Widespread Influence of 3’-End Structures on Mammalian miRNA Processing and Stability. Cell 169, 905–917.e11.
16. Brenneman, G.P., and Henshall, D.C. (2018). microRNAs in the pathophysiology of epilepsy. Neurosci. Lett. 667, 47–52.
17. Jimenez-Mateos, E.M., Engel, J., Merino-Serrais, P., McKiernan, R.C., Tanaka, K., Mour, G., Sano, T., O’Tuauthagh, C., Waddington, J.L., Prenter, S., et al. (2012). Silencing microRNA-134 promotes neuroprotective and prolonged seizure-suppressive effects. Nat. Med. 18, 1087–1094.
18. Hu, K., Xie, Y.Y., Zhang, C., Ouyang, D.S., Long, H.Y., Sun, D.N., Long, L.L., Feng, L., Li, Y., and Xiao, B. (2012). MicroRNA expression profile of the hippocampus in a rat model of temporal lobe epilepsy and miR-34a-targeted neuroprotection against hippocampal neuron cell apoptosis post-status epilepticus. BMC Neurosci. 13, 115.
19. Li, C., Li, S., Zhang, F., Wu, M., Liang, H., Song, J., Lee, C., and Chen, H. (2018). Endothelial microparticles-mediated transfer of microRNA-19b promotes atherosclerosis via activating perivascular adipose tissue inflammation in apolipoprotein e-/- mice. Biochem. Biophys. Res. Commun. 495, 1922–1929.
20. Beschke, C.R., and Henshall, D.C. (2015). microRNA and Epilepsy. Adv. Exp. Med. Biol. 888, 41–70.
21. Saunders, M.A., Liang, H., and Li, W.H. (2007). Human polymorphism at microRNAs and microRNA target sites. Proc. Natl. Acad. Sci. USA 104, 3300–3305.
22. Duan, R., Pak, C., and Jin, P. (2007). Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum. Mol. Genet. 16, 1124–1131.
23. Manna, I., Labate, A., Mumoli, L., Pantusa, M., Ferlazzo, E., Guigo, U., Quattrone, A., and Gambardella, A. (2013). Relationship between genetic variant in premicroRNA-146a and genetic predisposition to temporal lobe epilepsy: a case-control study. Gene 516, 181–183.
24. Markopoulos, G.S., Roupakia, E., Tsakamis, M., Chavdoula, E., Hatzipostolou, M., Polytarchou, C., Marou, R., Papavassiliou, A.G., Sandalzopoulo, R., and Kolettas, E. (2017). A step-by-step microRNA guide to cancer development and metastasis. Cell Oncol. (Dordr.) 40, 303–339.
25. Wang, Y., Yang, Z., and Le, W. (2017). Tiny But Mighty: Promising Roles of MicroRNAs in the Diagnosis and Treatment of Parkinson’s Disease. Neurosci. Bull. 33, 543–551.
26. Delghani, R., Rahman, F., and Rezaei, N. (2018). MicroRNA in Alzheimer’s disease revisited: implications for major neuropsychological mechanisms. Rev. Neurosci. 29, 161–182.
27. Quinlan, S., Kenny, A., Medina, M., Engel, T., and Jimenez-Mateos, E.M. (2017). MicroRNAs in Neurodegenerative Diseases. Int. Rev. Cell Mol. Biol. 334, 309–343.

28. Hemnall, D.C. (2013). MicroRNAs in the pathophysiology and treatment of status epilepticus. Front. Mol. Neurosci. 6, 37.

29. Song, Y.J., Tian, X.B., Zhang, S., Zhang, Y.X., Li, X., Li, D., Cheng, Y., Zhang, J.N., Kang, C.S., and Zhao, W. (2011). Temporal lobe epilepsy induced different expression of hippocampal miRNAs including let-7e and miR-23a/b. Brain Res. 1387, 134–140.

30. Kan, A.A., van Erp, S., Derjick, A.A., de Wit, M., Hessel, E.V., O’Dubhrib, E., de Jager, W., Van Rijen, P.C., Gosselaar, P.H., de Graan, P.N., and Pasterkamp, R.J. (2012). Genome-wide microRNA profiling of human temporal lobe epilepsy identifies modulators of the immune response. Cell. Mol. Life Sci. 69, 3127–3145.

31. Bot, A.M., Debski, K.J., and Lukasik, K. (2013). Alterations in miRNA levels in the dentate gyrus in epileptic rats. PLoS ONE 8, e67051.

32. Gorter, J.A., Iyer, A., White, I., Cozli, A., van Vliet, E.A., Sioudiya, S., and Aronica, E. (2014). Hippocampal subregion-specific microRNA expression during epileptogenesis in experimental temporal lobe epilepsy. Neurobiol. Dis. 62, 508–520.

33. Aronica, E., Flutter, K., Iyer, A., Zurolo, E., Vreijling, J., van Vliet, E.A., Baayen, J.C., and Gorter, J.A. (2010). Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy. Eur. J. Neurosci. 32, 1100–1107.

34. Jackson, D.B. (2009). Serum-based microRNAs: are we blinded by potential? Proc. Natl. Acad. Sci. USA 106, E5.

35. Kikov, T., Nakagawa, K., Tsuduki, T., Furukawa, K., Arai, H., and Miyazawa, T. (2014). MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer’s disease. J. Alzheimers Dis. 38, 1071–1080.

36. Kishimoto, T., Mizuta, H., and Iwai, Y. (2009). MicroRNA-124 and -137 cooperativity controls caspase-3 activity through neuroprotective mechanisms. J. Neurosci. 33, 1349–1356.

37. Loscher, W. (2011). Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 20, 359–368.

38. Gu, B., and Dalton, K.A. (2017). Models and detection of spontaneous recurrent seizures in laboratory rodents. Zool. Res. 38, 171–179.

39. Thom, M. (2014). Review: Hippocampal sclerosis in epilepsy: a neuropathology review. Neuropathol. Appl. Neurobiol. 40, 520–543.

40. van Vliet, E.A., Puhakka, N., Mills, J.D., Srivastava, P.K., Johnson, M.R., Roncon, P., Das Gupta, S., Karttunen, I., Simonato, M., Lukasiuk, K., et al. (2017). Standardization procedure for plasma biomarker analysis in rat models of epileptogenesis: Focus on circulating microRNAs. Epilepsia 58, 2013–2024.

41. Ma, Y. (2018). The challenge of microRNA as a Biomarker of Epilepsy. Curr. Neuropharmacol. 16, 37–42.

42. Ha, M., and Kim, V.N. (2014). Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15, 509–524.

43. Li, M., Marin-Muller, C., Bharadwaj, U., Chow, K.H., Yao, Q., and Chen, C. (2009). MicroRNAs: control and loss of control in human physiology and disease. World J. Surg. 33, 667–684.

44. Schaefer, A., O’Carroll, D., Tan, C.L., Hillman, D., Sugimori, M., Llinas, R., and Greengard, P. (2007). Cerebellar neurodegeneration in the absence of microRNAs. J. Exp. Med. 204, 1553–1558.

45. Liu, L., Liu, L., Shi, J., Tan, M., Xiong, J., Li, X., Hu, Q., Yi, Z., and Mao, D. (2016). MicroRNA-34b mediates hippocampal astrocyte apoptosis in a rat model of recurrent seizures. BMC Neurosci. 17, 56.

46. Bencurova, P., Baloun, J., Musilova, K., Radova, I., Tichy, B., Pail, M., Zeman, M., Brichtova, E., Hermanova, M., Pospisilova, S., et al. (2017). MicroRNA and mesial temporal lobe epilepsy with hippocampal sclerosis: Whole miRNAome profiling of human hippocampus. Epilepsia 58, 1782–1793.

47. Fromm, B., Billipp, T., Peck, J., Johansen, M., Tarver, J.E., King, B.L., Newcomb, J.M., Sempere, I.F., Flatmark, K., Hovig, E., and Peterson, K.J. (2015). A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome. Annu. Rev. Genet. 49, 213–242.

48. Korkotian, A., Mills, J.D., Gorter, J.A., van Vliet, E.A., and Aronica, E. (2017). Systematic review and meta-analysis of differentially expressed miRNAs in experimental and human temporal lobe epilepsy. Sci. Rep. 7, 11592.

49. Fabregat, A., Sidirooulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., Jupe, S., Körnering, F., McKay, S., et al. (2016). The Reactome pathway Knowledgebase. Nucleic Acids Res. 44 (D1), D481–D487.

50. Nishimura, D. (2004). BioCarta. Biotech Softw. Internet Rep.
104. Kapur, J. (2003). Role of Neuronal Loss in the Pathogenesis of Recurrent Spontaneous Seizures. Epilepsy Curr. 3, 166–167.

105. Fededa, J.P., Erik, C., Microwa, B., Stanyte, R., Yuan, S., Zheng, H., Ebnet, K., Yan, W., Knoblich, J.A., and Gerlich, D.W. (2016). MicroRNA-34a/449 controls mitotic spindle orientation during mammalian cortex development. EMBO J. 35, 2386–2398.

106. Chen, F., and Hu, S.J. (2012). Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. J. Biochem. Mol. Toxicol. 26, 79–86.

107. Sano, T., Reynolds, J.P., Jimenez-Mateos, E.M., Matsushima, S., Taki, W., and Knoblich, J.A., and Gerlich, D.W. (2016). MicroRNA-34a upregulation during seizure-induced neuronal death. Cell Death Dis. 3, e287.

108. Yang, X., Tang, X., Sun, P., Shi, Y., Liu, K., Hassan, S.H., Stetler, R.A., Chen, J., and Yin, K.J. (2017). MicroRNA-15a/16-1 Antagomir Ameliorates Ischemic Brain Injury in Experimental Stroke. Stroke 48, 1941–1947.

109. Narkhiati, S., and Pitkanen, A. (2005). Caspase 6 expression in the rat hippocampus during epileptogenesis and epilepsy. Neuroscience 131, 887–897.

110. Friedman, L.K., Mancuso, J., Patel, A., Kudur, V., Leheste, J.R., Iacobas, S., Botta, J., Iacobas, D.A., and Spray, D.C. (2013). Transcriptome profiling of hippocampal CA1 after early-life seizure-induced preconditioning may elucidate new genetic therapies for epilepsy. Eur. J. Neurosci. 38, 2139–2152.

111. Liu, R., Liu, C., Chen, D., Yang, W.H., Liu, X., Liu, C.G., Dugas, C.M., Tang, F., Zheng, P., Liu, Y., and Wang, L. (2015). FOXP3 Controls an miR-146/NF-kappaB Negative Feedback Loop That Inhibits Apoptosis in Breast Cancer Cells. Cancer Res. 75, 1703–1713.

112. Park, H., Huang, X., Lu, C., Cairo, M.S., and Zhou, X. (2015). MicroRNA-146a and microRNA-146b regulate human dendritic cell apoptosis and cytokine production by targeting TRAF6 and IRAK1 proteins. J. Biol. Chem. 290, 2831–2841.

113. Tao, H., Zhao, J., Liu, T., Cai, Y., Zhou, X., Xing, H., Wang, Y., Yin, M., Zhong, W., Liu, Z., et al. (2017). Intranasal Delivery of miR-146a Mimics Delayed Seizure Onset in the Lithium-Pilocarpine Mouse Model. Mediators Inflamm. 2017, 6512626.

114. Liu, W., Liu, S.Y., He, Y.B., Huang, R.L., Deng, S.Y., Ni, G.X., and Yu, B. (2017). MiR-451 suppresses proliferation, migration and promotes apoptosis of the human osteosarcoma by targeting macrophage migration inhibitory factor. Biomed. Pharmacother. 87, 621–627.

115. Peng, Z., and Zhang, Y. (2016). Propofol inhibits proliferation and accelerates apoptosis of human gastric cancer cells by regulation of microRNA-451 and MMP-2 expression. Genet. Mol. Res. 15, gm7078.

116. Drusco, A., Bottone, A., Lagana, A., Acunzo, M., Fassan, M., Cascione, L., Antenucci, A., Kumchala, P., Vicentini, C., Gardiman, M.P., et al. (2015). A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. Oncotarget 6, 20829–20839.

117. Kim, Y., Powathil, G., Kang, H., Trusc, D., Kim, H., Lawler, S., and Chaplain, M. (2015). Strategies of eradicating glioma cells: a multi-scale mathematical model with MiR-451-AMPK-mTOR control. PLoS ONE 10, e0114370.

118. Xue, T.F., Ding, X., Ji, J., Yan, H., Huang, J.Y., Guo, X.D., Yang, J., and Sun, X.L. (2017). PDX149163 induces hypothermia to protect against brain injury in acute cerebral ischemic rats. J. Pharmacol. Sci. 135, 105–113.

119. Iori, V., Iyer, A.M., Ravizza, T., Beltrame, L., Paracchini, L., Marchini, S., Cerovic, M., Hill, C., Ferrari, M., Zucchetti, M., et al. (2017). Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy. Neurobiol. Dis. 99, 12–23.

120. He, F., Liu, B., Meng, Q., Sun, Y., Wang, W., and Wang, C. (2016). Modulation of miR-146a/complement factor H-mediated inflammatory responses in a rat model of temporal lobe epilepsy. Bioc. Rep. 36, e04433.

121. Li, T.R., Jia, Y.J., Ma, C., Qiu, W.Y., Wang, Q., Shao, X.Q., and Lv, R.J. (2018). The role of the microRNA-146a/complement factor H/interleukin-1-b mediated inflammatory loop circuit in the perpetuate inflammation of chronic temporal lobe epilepsy. Dis. Model. Mech. 11, dmm031708.

122. Lin, X., Chen, W., Wei, F., Zhou, B.P., Hung, M.C., and Xie, X. (2017). Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly. Theranostics 7, 4805–4824.

123. Huang, Y., Guo, J., Wang, Q., and Chen, Y. (2014). MicroRNA-132 silencing decreases the spontaneous recurrent seizures. Int. J. Clin. Exp. Med. 7, 1639–1649.

124. Danis, B., van Rikxoort, M., Kretschmann, A., Zhang, J., Godard, P., Andonovic, L., Siegel, F., Niehusmann, P., Hanon, E., Delev, D., et al. (2016). Differential expression of miR-184 in temporal lobe epilepsy patients with and without hippocampal sclerosis - Influence on microglial function. Sci. Rep. 6, 33943.

125. Gu, Z., Gu, L., Eils, R., Schlesner, M., and Broers, B. (2014). circize Implements and enhances circular visualization in R. Bioinformatics 30, 2811–2812.